Details for New Drug Application (NDA): 220483
✉ Email this page to a colleague
NDA 220483 describes NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, which is a drug marketed by Baxter Hlthcare Corp and Sagent and is included in three NDAs. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
Summary for 220483
| Tradename: | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE |
| Applicant: | Sagent |
| Ingredient: | norepinephrine bitartrate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 220483
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | ||||
| Approval Date: | Mar 26, 2026 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
